NuPathe dumps Endo

NuPathe decided Teva's $144-million offer was a better fit, ending its possible Endo merger.

January 22, 2014

6:38 pm

Teva has swept in and upset Endo’s NuPathe merger. Endo issued a statement Monday that NuPathe rejected Endo’s bid, which meant coughing up a $5-million termination fee in order to go forward with Teva.

Specialty pharmaceutical company Endo offered $104 million for the company, but Business Week says Teva topped this by offering $144 million.

The deal means NuPathe’s Zecuity migraine patch will now belong to Teva.

From Our Partners

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.

Partner Content

The new brand.com experience

How healthcare manufacturers can improve customer engagement, drive high-value activity and inform future strategy with conversational AI.

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

Partner Content

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

The Healthcare Marketers Trend Survey shows that, as far as channel usage goes, more growth occurred in newer tactics like non-linear video and streaming audio than in some of the more traditional ones.

A Big C Shift: Rebranding cancer to reflect advances in oncology

Partner Content

A Big C Shift: Rebranding cancer to reflect advances in oncology

Pivoting people’s perception of the disease to match the realities of treatment.